Meduloc Raises $4M Series B to Advance Orthopedic Fracture Fixation Platform
Top Picks
Stay Ahead of the Market
Get the latest startup funding, hiring trends and global opportunities delivered to your inbox every week.
Meduloc Secures $4 Million Series B Funding
Pennsylvania-based orthopedic medical device company Meduloc has raised $4 million in Series B funding to advance its innovative fracture fixation technology and prepare for commercial expansion.
The funding round was led by GenHenn Capital, with participation from Life Sciences Greenhouse Investments (LSGI), Ben Franklin Technology Partners of Southeastern Pennsylvania, Broad Street Angels, former Los Angeles Dodgers player Andre Ethier, and several existing and new investors.
Advancing Orthopedic Fracture Treatment
Led by Sarah Sachinis, President and CEO, Meduloc develops orthopedic medical devices designed to improve fracture fixation for both adult and pediatric patients.
Its flagship technology is an FDA-cleared, sterile, single-use flexible nitinol intramedullary platform, engineered for long-bone fracture applications.
The platform is designed to:
Provide stable fracture fixation
Preserve natural bone anatomy
Offer surgeons a versatile treatment alternative
Support a wide range of long-bone fracture procedures
By using flexible nitinol technology, Meduloc aims to improve surgical outcomes while simplifying fracture management.
Funding to Support Commercial Launch
The newly raised capital will be used to:
Support the controlled alpha launch of its fracture fixation platform
Continue generating clinical evidence
Expand commercial infrastructure
Prepare for broader adoption among orthopedic surgeons and healthcare providers
The investment marks an important milestone as the company moves from product development toward commercialization.
Leadership
Meduloc is led by Sarah Sachinis, who serves as President and CEO.
The company is headquartered in West Chester, Pennsylvania, USA.
